YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MOND…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is C4 Therapeutics, Inc. (CCCC) one of those stocks right now? Let's take a closer look at the stock's…
(RTTNews) - Friday's Top Gainers included Replimune, which is preparing to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma; Clearmind Medicine, which strengthened its global intellectual property portfolio thr…
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 1% on Wednesday. The Dow traded down 0.24% to 49,638.96 while the NASDAQ gained 1.18% to 26,395.66. The S&P 500 also rose, gaining, 0.60% to 7,445.55.…
U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Wednesday. Shares of Vishay Intertechnology Inc(NYSE:VSH) rose sharply after the company reported better-than-expected first-quarter financial results and is…
C4 Therapeutics, Inc. Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab Additional Phase…
Company Logo The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation. Opportunities lie in emerging the…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Roche Holding (SWX:ROP) has entered into a collaboration with C4 Therapeutics to develop degrader antibody conjugates f…
(RTTNews) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate or DAC, modality. C4 Therapeutics and Roche will collaborate on two…
C4 Therapeutics, Inc. Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T t…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is C4 Therapeutics, Inc. (CCCC) one of those stocks right now? A quick glance at the company's year-to-…
C4 Therapeutics, Inc. (NASDAQ:CCCC) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. According to CNN’s compilation of price targets, all 8 analysts covering C4 Therapeutics, Inc. (NASDAQ:CCCC) are bullish. The median price t…
C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the 11 most popular AI penny stocks to buy now. On February 23, Brookline increased the firm’s price target on C4 Therapeutics Inc. (NASDAQ:CCCC) from $20 to $30, while maintaining its Buy ratin…
WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent d…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has BrightSpring Health Services, Inc. (BTSG) been one of those stocks this year? A quick glance at the…
C4 Therapeutics, Inc. (NASDAQ:CCCC) is included in our list of the 7 most volatile stocks under $5 for day trading.Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential As of February 16, 2026, all…
We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC. C4 Therapeutics, Inc.'s share was trading at $1.9600 as of January 29th. Copyright: dolga…
WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent di…
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery Strategy Progressing Effor…
C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the best biotech penny stocks to buy according to analysts. On December 17, Barclays lowered the firm’s price target on C4 Therapeutics to $5 from $10, while maintaining an Overweight rating on…
Biogen’s fair value estimate has seen a modest uptick, now set at $178.07 compared to the previous $176.72. This change reflects slightly improved analyst confidence, supported by optimism around policy headwinds and progress in the compan…
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management wil…
[Shares Certificate] Bluberries * C4 Therapeutics (CCCC [https://seekingalpha.com/symbol/CCCC]) has filed a shelf registration to offer up to $400M in securities. * The offering [https://seekingalpha.com/filing/52651167] may include common…
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximate…
* C4 Therapeutics press release [https://seekingalpha.com/pr/20296363-c4-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-highlights] (CCCC [https://seekingalpha.com/symbol/CCCC]): Q3 GAAP EPS of -$0.44 misses…
C4 Therapeutics, Inc. Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Pha…
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.1 per share a year ago. These figures are adjusted for non-recurring i…
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential…
Amid a backdrop of fluctuating stock indices, with the Nasdaq recently hitting a record high before retreating due to geopolitical tensions, investors are keenly observing market dynamics. Penny stocks, often seen as relics of past trading…
C4 Therapeutics, Inc. WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced t…
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Populat…
Biogen recently announced that the U.S. FDA has accepted its investigational new drug (IND) application for BIIB142, an IRAK4 degrader developed in partnership with C4 Therapeutics, for exploration in autoimmune diseases. This milestone hi…
Here are the top movers in Monday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT ATCH [https://www.chartmill.com/stock/quote/ATCH/profile] 148.0% ATLASCLEAR HOLDINGS INC'S (NYSEAR…
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT ATCH [https://www.chartmil…
C4 Therapeutics, Inc. Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical com…
* C4 Therapeutics press release [https://seekingalpha.com/pr/20192750-c4-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-highlights] (NASDAQ:CCCC [https://seekingalpha.com/symbol/CCCC]): Q2 GAAP EPS of -$0.37…